CA IX Monoclonal Antibody(12F10)

Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes known. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It may be involved in cell proliferation and transformation. This gene was mapped to 17q21.2 by fluorescence in situ hybridization, however, radiation hybrid mapping localized it to 9p13-p12.

Introducing the CA IX Monoclonal Antibody (12F10), a cutting-edge product designed to revolutionize the field of cancer research and diagnostics. This highly specialized antibody is meticulously developed to target and detect Carbonic Anhydrase IX (CA IX), a key biomarker associated with various types of cancer.

The CA IX Monoclonal Antibody (12F10) is meticulously engineered using state-of-the-art technology, ensuring exceptional specificity and sensitivity. Its unique binding properties enable precise identification and localization of CA IX in tissue samples, facilitating accurate diagnosis and prognosis of cancer patients.

With its exceptional performance, the CA IX Monoclonal Antibody (12F10) offers researchers and clinicians an invaluable tool for studying the role of CA IX in tumorigenesis, metastasis, and therapeutic response. Its application extends to a wide range of research areas, including immunohistochemistry, immunofluorescence, and flow cytometry.

This product is manufactured under stringent quality control measures, guaranteeing batch-to-batch consistency and reproducibility. Each vial of the CA IX Monoclonal Antibody (12F10) is meticulously tested to ensure optimal performance, providing researchers and clinicians with reliable and accurate results.

The CA IX Monoclonal Antibody (12F10) is supplied in a convenient and user-friendly format, allowing for easy integration into existing laboratory protocols. Its long shelf life ensures prolonged usability, making it a cost-effective solution for laboratories and research institutions.

In summary, the CA IX Monoclonal Antibody (12F10) is a cutting-edge product that offers exceptional specificity, sensitivity, and reliability in the detection and localization of CA IX. With its wide range of applications and stringent quality control measures, this antibody is poised to revolutionize cancer research and diagnostics.